Post by ProductLife Group

𝗦𝘁𝗿𝗼𝗻𝗴 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗮𝗹𝘄𝗮𝘆𝘀 𝗹𝗲𝗮𝗱 𝘁𝗼 𝘀𝘁𝗿𝗼𝗻𝗴 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.   In many cases, the issue is not a lack of robust data. It is the inability to translate that data into a form that resonates with the people responsible for acting on it. Clinical leaders, healthcare managers and policymakers interpret value through fundamentally different lenses, each shaped by distinct priorities and constraints and the same evidence can be read very differently depending on governance structures and decision-making dynamics. In a new article Héctor D. de Paz Fernández, PhD, from Outcomes'10, a ProductLife Group 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, explores how Social Return on Investment (SROI) can serve as a translation framework for this exact problem. Rather than treating clinical, economic and social impact as separate analyses that risk generating conflicting interpretations, SROI integrates them into a single, coherent narrative built around one deliberately simple output: a ratio that expresses the value generated for each unit of investment.    What makes the framework genuinely useful is not the metric itself but what it enables. The same analysis can speak to a clinician in terms of patient outcomes, to a healthcare manager in terms of resource efficiency and to a policymaker in terms of societal impact, without losing coherence across those perspectives. In environments where governance is decentralised and decision-making dynamics vary by setting, as is often the case in Spain, that kind of consistency is not a nice-to-have. It is what allows well-supported interventions to actually gain traction.    📖 Read the full article: https://lnkd.in/gbgX53wf 📩 Contact our experts to discuss your value demonstration and market access strategy: https://lnkd.in/eZaf8mQE   #ProductLifeGroup #Outcomes10 #MarketAccess #HealthEconomics #SROI #ValueBasedHealthcare #HTA #LifeSciences #Spain